Form 4 Tracker
Entrada Therapeutics, Inc.
TRDA

21 insider filings · Latest: Aug 6, 2026

Common Stock Transactions
Txn DateAcceptedInsiderTypeSharesAvg PriceValueShares OwnedFiling
Aug 10, 2026Aug 10 11:54 PMKush ParmarDirector
Sale
92,444$7.00$647.1K2,691,337(I)

View →

Aug 7, 2026Aug 10 11:54 PMKush ParmarDirector
Sale
52,317$6.85$358.4K2,783,781(I)

View →

Aug 6, 2026Aug 10 11:54 PMKush ParmarDirector
Sale
10,494$7.00$73.5K2,836,098(I)

View →

Aug 7, 2026Aug 10 11:52 PM5AM Ventures V, L.P.10% Owner
Sale
52,317$6.85$358.4K2,783,781(D)

View →

Aug 6, 2026Aug 10 11:52 PM5AM Ventures V, L.P.10% Owner
Sale
10,494$7.00$73.5K2,836,098(D)

View →

Jul 30, 2026Aug 10 11:50 PM5AM Ventures V, L.P.
Proposed Sale
331,156$6.55$2.2M

View →

Jul 31, 2026Aug 3 9:32 PM5AM Ventures V, L.P.10% Owner
Sale
1,718$6.85$11.8K2,846,592(D)

View →

Jul 30, 2026Aug 3 9:32 PM5AM Ventures V, L.P.10% Owner
Sale
114,756$6.93$795.3K2,848,310(D)

View →

Jul 31, 2026Aug 3 9:26 PMKush ParmarDirector, 10% Owner
Sale
1,718$6.85$11.8K2,846,592(I)

View →

Jul 30, 2026Aug 3 9:26 PMKush ParmarDirector, 10% Owner
Sale
114,756$6.93$795.3K2,848,310(I)

View →

Jul 30, 2026Jul 30 9:39 PM5AM Ventures V, L.P.
Proposed Sale
331,156$6.55$2.2M

View →

May 20, 2026May 21 8:31 PMBernhardt G ZeiherDirector
Purchase
5,000$5.86$29.3K5,000(I)

View →

May 4, 2026May 4 11:25 PMNatarajan SethuramanPresident, Research & Develop.
Sale
25,907$15.39$398.8K216,317(D)

View →

May 4, 2026May 4 11:24 PMNathan J DowdenPresident & COO
Sale
15,000$15.33$230.0K198,588(D)

View →

May 4, 2026May 4 8:33 PMNATHAN DOWDEN
Proposed Sale
15,000$14.50$217.5K

View →

May 4, 2026May 4 8:32 PMNATARAJAN SETHURAMAN
Proposed Sale
25,907$14.50$375.7K

View →

Apr 1, 2026Apr 2 8:39 PMKory James WentworthChief Financial Officer
Sale
2,500$12.95$32.4K119,010(D)

View →

Apr 1, 2026Apr 1 8:38 PMKORY WENTWORTH
Proposed Sale
2,500$12.62$31.6K

View →

Mar 10, 2026Mar 11 8:35 PMNathan J DowdenPresident & COO
Sale
11,894$13.05$155.2K198,588(D)

View →

Mar 9, 2026Mar 11 8:35 PMNathan J DowdenPresident & COO
Sale
3,116$13.02$40.6K210,482(D)

View →

Page 1 of 3

Next →

Stock Options & Derivatives
Txn DateAcceptedInsiderTypeSharesExercise PriceShares OwnedFiling
Jun 10, 2026Jun 12 9:34 PMKush ParmarDirector, 10% Owner
Grant/Award
19,000$5.9719,000(D)

View →

Jun 10, 2026Jun 12 9:17 PMPeter S KimDirector
Grant/Award
19,000$5.9719,000(D)

View →

Jun 10, 2026Jun 12 9:16 PMGina ChapmanDirector
Grant/Award
19,000$5.9719,000(D)

View →

Jun 10, 2026Jun 12 9:05 PMMaha RadhakrishnanDirector
Grant/Award
19,000$5.9719,000(D)

View →

Jun 10, 2026Jun 12 9:01 PMMary ThistleDirector
Grant/Award
19,000$5.9719,000(D)

View →

Jun 10, 2026Jun 12 8:52 PMBernhardt G ZeiherDirector
Grant/Award
19,000$5.9719,000(D)

View →

May 4, 2026May 4 11:24 PMNathan J DowdenPresident & COO
Option Exercise
15,000$1.7449,831(D)

View →

Mar 1, 2026Mar 3 11:21 PMDipal DoshiDirector, CEO
Grant/Award
208,000$11.93208,000(D)

View →

Mar 1, 2026Mar 3 11:20 PMKory James WentworthChief Financial Officer
Grant/Award
66,600$11.9366,600(D)

View →

Mar 1, 2026Mar 3 11:19 PMNathan J DowdenPresident & COO
Grant/Award
83,200$11.9383,200(D)

View →

Mar 1, 2026Mar 3 11:18 PMNatarajan SethuramanPresident, Research & Develop.
Grant/Award
83,200$11.9383,200(D)

View →